A pharmaceutical company user's perspective on the potential of high content screening in drug discovery.

It is early to fully reflect on the state of the art in high content screening (HCS), because it is still a relatively new approach in drug discovery. Although the development of the first microscopes are a century old and the first confocal microscope is only 20 yr old, the fluorescent probes used within HCS along with the combination of robotic automation and integrated software technologies are quite new. HCS will require a few more years to fully demonstrate its potential power in drug discovery. Within the last year, however, one has seen this ever-expanding field lure participants in from all areas of science, introducing newer versions of instruments and reagents such that the combined efforts result in platforms and tools that meet many organizational goals in multiple ways. The potential of HCS today lies in its versatility. HCS can be used for primary screening, basic research, target identification, biomarkers, cytotoxicity, and helping to predict clinical outcomes. HCS is being applied to stem cells, patient cells, primary hepatocytes, and immortalized cultured cells. We have noted for individual specialized assays, there are multiple solutions just as there are for those standardized universally accepted assays. Whether we have needed to query cellular processes under live conditions or wanted to follow kinetically the course of a compound's effects on particular cellular reactions, we have been hampered by only a few limitations. This chapter offers a glimpse inside the use of HCS in our drug discovery environment.

[1]  John Hallam,et al.  Artificial intelligence and robotics in high throughput post-genomics. , 2005, Drug discovery today.

[2]  Thomas Tuschl,et al.  Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. , 2003, Antisense & nucleic acid drug development.

[3]  Christine C. Hudson,et al.  TRANSFLUOR® Provides a Universal Cell-Based Assay for Screening G-Protein–Coupled Receptors , 2005 .

[4]  Thomas Kost,et al.  BacMam recombinant baculoviruses in G protein-coupled receptor drug discovery. , 2004, Receptors & channels.

[5]  M. Fenech.  In vitro micronucleus technique to predict chemosensitivity. , 2005, Methods in molecular medicine.

[6]  Hubert C Chen,et al.  Determination of adipocyte size by computer image analysis. , 2002, Journal of lipid research.

[7]  D. L. Taylor,et al.  High content screening applied to large-scale cell biology. , 2004, Trends in biotechnology.

[8]  Ahlberg.  Visual exploration of HTS databases: bridging the gap between chemistry and biology. , 1999, Drug discovery today.

[9]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[10]  M. Caron,et al.  Molecular mechanisms of G protein-coupled receptor signaling: role of G protein-coupled receptor kinases and arrestins in receptor desensitization and resensitization. , 1997, Receptors & channels.